Lonza’s $1.2B Roche Biologics Plant Buy Reshapes CDMO Market


Lonza, a leading Swiss contract development and manufacturing organization (CDMO), has acquired Roche’s biologics manufacturing facility in Vacaville, California, for $1.2 billion in cash. The deal, which closed on November 1, 2021, positions Lonza as a major player in the rapidly growing biologics manufacturing market.

The Vacaville site is one of the largest and most advanced biologics manufacturing facilities in the world, with over 1 million square feet of space and a production capacity of over 200,000 liters. The acquisition will significantly expand Lonza’s global manufacturing network and enhance its ability to meet the increasing demand for biologics, such as monoclonal antibodies and cell therapies.

The move reflects the growing importance of the CDMO market, as more pharmaceutical and biotech companies outsource their manufacturing operations to specialized providers like Lonza. The global CDMO market is expected to reach $136 billion by 2026, driven by the increasing complexity of biologics and the need for flexible, scalable manufacturing solutions.